454 related articles for article (PubMed ID: 24780112)
41. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
[TBL] [Abstract][Full Text] [Related]
42. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.
Yang SC; Grimm EA; Parkinson DR; Carinhas J; Fry KD; Mendiguren-Rodriguez A; Licciardello J; Owen-Schaub LB; Hong WK; Roth JA
Cancer Res; 1991 Jul; 51(14):3669-76. PubMed ID: 1648441
[TBL] [Abstract][Full Text] [Related]
43. Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy.
Schabowsky RH; Madireddi S; Sharma R; Yolcu ES; Shirwan H
Curr Opin Investig Drugs; 2007 Dec; 8(12):1002-8. PubMed ID: 18058571
[TBL] [Abstract][Full Text] [Related]
44. [Clinical significance of CD4+ CD25+ regulatory T-cells detection in tumor-draining lymph nodes of nonsmall cell lung cancer patients].
Su YJ; Ren K; Li H; Ren XB; Wang CL
Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):922-6. PubMed ID: 18478932
[TBL] [Abstract][Full Text] [Related]
45. Predictive value of peripheral regulatory T cells in non-small cell lung cancer patients undergoing radiotherapy.
Liu C; Wu S; Meng X; Liu G; Chen D; Cong Y; Shen G; Sun B; Wang W; Wang Q; Gao H; Liu X
Oncotarget; 2017 Jun; 8(26):43427-43438. PubMed ID: 28624781
[TBL] [Abstract][Full Text] [Related]
46. Suppressive effects of gemcitabine plus cisplatin chemotherapy on regulatory T cells in nonsmall-cell lung cancer.
Chen C; Chen Z; Chen D; Zhang B; Wang Z; Le H
J Int Med Res; 2015 Apr; 43(2):180-7. PubMed ID: 25659373
[TBL] [Abstract][Full Text] [Related]
47. Randomized controlled phase III trial of adjuvant chemoimmunotherapy with activated cytotoxic T cells and dendritic cells from regional lymph nodes of patients with lung cancer.
Kimura H; Matsui Y; Ishikawa A; Nakajima T; Iizasa T
Cancer Immunol Immunother; 2018 Aug; 67(8):1231-1238. PubMed ID: 29855695
[TBL] [Abstract][Full Text] [Related]
48. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients.
Adotevi O; Pere H; Ravel P; Haicheur N; Badoual C; Merillon N; Medioni J; Peyrard S; Roncelin S; Verkarre V; Mejean A; Fridman WH; Oudard S; Tartour E
J Immunother; 2010; 33(9):991-8. PubMed ID: 20948437
[TBL] [Abstract][Full Text] [Related]
49. Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients.
Kotsakis A; Koinis F; Katsarou A; Gioulbasani M; Aggouraki D; Kentepozidis N; Georgoulias V; Vetsika EK
Sci Rep; 2016 Dec; 6():39247. PubMed ID: 27976733
[TBL] [Abstract][Full Text] [Related]
50. Cyclooxygenase-2 genetic variants influence intratumoral infiltration of Foxp3-positive regulatory T cells in non-small cell lung cancer.
Yukawa T; Shimizu K; Maeda A; Yasuda K; Saisho S; Okita R; Nakata M
Oncol Rep; 2015 Jan; 33(1):74-80. PubMed ID: 25338928
[TBL] [Abstract][Full Text] [Related]
51. Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects.
Schoenhals JE; Cushman TR; Barsoumian HB; Li A; Cadena AP; Niknam S; Younes AI; Caetano MDS; Cortez MA; Welsh JW
Front Immunol; 2018; 9():2170. PubMed ID: 30294332
[TBL] [Abstract][Full Text] [Related]
52. Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer.
Li JY; Duan XF; Wang LP; Xu YJ; Huang L; Zhang TF; Liu JY; Li F; Zhang Z; Yue DL; Wang F; Zhang B; Zhang Y
J Immunol Res; 2014; 2014():286170. PubMed ID: 24868562
[TBL] [Abstract][Full Text] [Related]
53. Regulatory (FoxP3
Koh J; Hur JY; Lee KY; Kim MS; Heo JY; Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Sci Rep; 2020 Nov; 10(1):18994. PubMed ID: 33149213
[TBL] [Abstract][Full Text] [Related]
54. Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients.
Kurose K; Ohue Y; Wada H; Iida S; Ishida T; Kojima T; Doi T; Suzuki S; Isobe M; Funakoshi T; Kakimi K; Nishikawa H; Udono H; Oka M; Ueda R; Nakayama E
Clin Cancer Res; 2015 Oct; 21(19):4327-36. PubMed ID: 26429981
[TBL] [Abstract][Full Text] [Related]
55. Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination.
Hansen GL; Gaudernack G; Brunsvig PF; Cvancarova M; Kyte JA
Cancer Immunol Immunother; 2015 Dec; 64(12):1609-21. PubMed ID: 26498005
[TBL] [Abstract][Full Text] [Related]
56. Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells.
Zhao WP; Zhu B; Duan YZ; Chen ZT
Oncol Rep; 2009 Jun; 21(6):1405-11. PubMed ID: 19424617
[TBL] [Abstract][Full Text] [Related]
57. Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function.
La Fleur L; Botling J; He F; Pelicano C; Zhou C; He C; Palano G; Mezheyeuski A; Micke P; Ravetch JV; Karlsson MCI; Sarhan D
Cancer Res; 2021 Feb; 81(4):956-967. PubMed ID: 33293426
[TBL] [Abstract][Full Text] [Related]
58. Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer.
Kimura H; Matsui Y; Ishikawa A; Nakajima T; Yoshino M; Sakairi Y
Cancer Immunol Immunother; 2015 Jan; 64(1):51-9. PubMed ID: 25262164
[TBL] [Abstract][Full Text] [Related]
59. Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab.
Yi JS; Ready N; Healy P; Dumbauld C; Osborne R; Berry M; Shoemaker D; Clarke J; Crawford J; Tong B; Harpole D; D'Amico TA; McSherry F; Dunphy F; McCall SJ; Christensen JD; Wang X; Weinhold KJ
Clin Cancer Res; 2017 Dec; 23(24):7474-7482. PubMed ID: 28951518
[No Abstract] [Full Text] [Related]
60. CCR4 mediated chemotaxis of regulatory T cells suppress the activation of T cells and NK cells via TGF-β pathway in human non-small cell lung cancer.
Liu W; Wei X; Li L; Wu X; Yan J; Yang H; Song F
Biochem Biophys Res Commun; 2017 Jun; 488(1):196-203. PubMed ID: 28487109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
